Fueling Next-Gen Medicine: Juno Therapeutics' $129M Boost and Strategic Merger with Bristol Myers Squibb

We are excited to announce that Juno Therapeutics has successfully raised $129,000,000 in its latest funding round—a strong vote of confidence in our mission to transform patient care for those battling severe illnesses.

This substantial funding milestone underscores our new identity following our merger with Bristol Myers Squibb, a union that has positioned us as a leading biopharma company.

Together, we are ideally equipped to discover, develop, and deliver innovative medicines, paving the way for breakthroughs in the treatment of cancer and other serious diseases.

The investment will be pivotal for rapidly advancing our research and clinical development programs, accelerating the journey of our promising therapies from the laboratory to the patient bedside.

The funds raised will specifically be allocated to expanding our cutting-edge research infrastructure, enhancing our clinical trial capabilities, and forging collaborations with other top-tier research organizations.

These efforts will drive our mission to create next-generation therapies and deliver transformative solutions for patients in need.

Our dedicated teams are already working around the clock to harness the latest scientific breakthroughs, ensuring that every innovation contributes to meaningful advances in healthcare.

For more detailed information on the strategic direction of this funding and its integration into our ongoing projects, we invite you to visit our website at www.bms.com to learn more about our work.

Additional insights and updates are available in our recent press release, which you can view at http://bit.ly/3UbQcnl.

This funding announcement marks a significant step in our journey, reaffirming our commitment to deliver hope and healing through pioneering science and unwavering dedication to patients worldwide.